TESAMORELIN

Tesamorelin is a synthetic analog of GHRH stabilized with a trans-3-hexenoic acid group that significantly extends its plasma half-life compared to native GHRH. It is studied for its potent GH-stimulating and body composition effects, and has received FDA approval for reduction of excess visceral adipose tissue in HIV-related lipodystrophy, making it one of the best-characterized GHRH analogs in clinical research.

Mechanism of Action

•        Binds to and activates GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH release more durably than native GHRH in research models.

•        Studied for elevation of IGF-1, which drives lipolysis in adipose tissue and anabolic signaling in muscle.

•        Research shows preferential reduction of visceral fat over subcutaneous fat, improving cardiometabolic markers.

•        Investigated for preservation of endogenous feedback regulation of the GH axis.

Research Areas

•        Visceral fat reduction and body composition biology.

•        GH deficiency and adult somatopause research.

•        Metabolic syndrome and cardiovascular risk factor biology.

•        Anti-aging research leveraging sustained IGF-1 elevation.

•        HIV-related lipodystrophy studies (FDA-approved research indication).

Presentation and Storage

Supplied as a lyophilized powder in a sealed vial containing 10mg of tesamorelin. Reconstitute with bacteriostatic water for laboratory use. Store at -20C.